And it depends on you how soon it will be developed
As equity investors caught up in the cannabis craze push pot stocks to record highs, options traders are paying the most ever to hedge against a comedown.
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Dialysis companies have poured $94 million into a campaign to defeat a California ballot initiative that would cap profit margins at their outpatient clinics, the most spending since pharmaceutical companies helped defeat a drug-price referendum two years ago.